J Code

ALL CODES   A CODE   B CODE   C CODE   CPT CODE   J CODE   NOC CODE   P CODE   Q CODE   S CODE

UZEDY – J2799

UZEDY is a Psychiatric drug manufactured by TEVA NEUROSCIENCE, INC. and administered via the Subcutaneous route of administration. The J Code: J2799 is aligned to the drug UZEDY.

Read More »

VYJUVEK – J3401

VYJUVEK is a Genetic Disorder drug manufactured by Krystal Biotech and administered via the Topical application route of administration. The J Code: J3401 is aligned to the drug VYJUVEK.

Read More »

HYDROXOCOBALAMIN – J3425

HYDROXOCOBALAMIN is a Hematology drug manufactured by ACTAVIS PHARMA, INC. and administered via the Intramuscular route of administration. The J Code: J3425 is aligned to the drug HYDROXOCOBALAMIN.

Read More »

CARMUSTINE – J9052

CARMUSTINE is a Oncology drug manufactured by ACCORD HEALTHCARE and administered via the Intravenous route of administration. The J Code: J9052 is aligned to the drug CARMUSTINE.

Read More »

CYCLOPHOSPHAMIDE (DR. REDDY’S) – J9072

CYCLOPHOSPHAMIDE (DR. REDDY’S) is a Oncology drug manufactured by Dr. Reddy’s Laboratories Inc. and administered via the Intravenous route of administration. The J Code: J9072 is aligned to the drug CYCLOPHOSPHAMIDE (DR. REDDY’S).

Read More »

DOCETAXEL – J9172

DOCETAXEL is a Oncology drug manufactured by INGENUS and administered via the route of administration. The J Code: J9172 is aligned to the drug DOCETAXEL.

Read More »

METHOTREXATE – J9255

METHOTREXATE is a Oncology drug manufactured by ACCORD HEALTHCARE and administered via the route of administration. The J Code: J9255 is aligned to the drug METHOTREXATE.

Read More »

COLUMVI – J9286

COLUMVI is a Oncology drug manufactured by GENENTECH, INC. and administered via the Intravenous route of administration. The J Code: J9286 is aligned to the drug COLUMVI.

Read More »

EPKINLY – J9321

EPKINLY is a Oncology drug manufactured by GENMAB US, INC. and administered via the Subcutaneous route of administration. The J Code: J9321 is aligned to the drug EPKINLY.

Read More »